Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Amgen ( NASDAQ:AMGN )
Greenlight Capital shifts its portfolio, betting on construction and fashion while parting ways with medical imaging. Einhorn's hedge fund optimizes its investment strategy, signaling confidence in new picks and skepticism in former holdings.
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.
Why Amgen ( AMGN ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Is Trending Stock Amgen Inc. ( AMGN ) a Buy Now?
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Why Is Amgen Stock Falling Wednesday? - Amgen ( NASDAQ:AMGN )
Amgen Q2 EPS of $6.02 beats estimates, with 21% YoY growth. Revenue rose 9% to $9.18 billion, driven by 13% volume growth. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. Amgen Inc.
Eli Lilly, Amgen In Legal Fight Over Drug Discount Program - Eli Lilly ( NYSE:LLY ) , Amgen ( NASDAQ:AMGN )
Amgen, Eli Lilly, and UCB allege HHS wrongly certified ineligible clinics under 340B. A federal court denied HHS's motion to dismiss key parts of the lawsuit. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday.
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
Amgen ( AMGN ) Q2 Profit Jumps 21%
Amgen ( NASDAQ:AMGN ) , a leading biotechnology company with a wide portfolio of innovative medicines, released its second-quarter 2025 results on August 5, 2025. The headline news was a double-digit jump in profit and a 9% increase in revenue, beating analyst predictions ( non-GAAP EPS and GAAP ...
Small-Caps Stay Higher, Other Indexes Dwindle
President Trump mentioned adding new tariffs on semiconductor imports, which helped move markets aside from the Russell 2000 lower.
Amgen ( AMGN ) Beats Q2 Earnings and Revenue Estimates
Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Trade Deficit Narrowed More Than Expected
Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.
Pre-markets Slightly Up on Mostly Good Q2 Earnings
Q2 earnings reports are overall posting favorable results, including this morning ahead of the open.
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Selloff? What Selloff? Monday Market Rebound
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Regeneron Reports Second Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the second quarter of 2025 and provided a business update.
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gear Up for Amgen ( AMGN ) Q2 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Why Is Soligenix Stock Soaring On Thursday? - Soligenix ( NASDAQ:SNGX )
SGX945 showed 40% ulcer reduction vs. placebo at Week 4, beating apremilast's 37% despite shorter treatment. SGX945 showed no adverse events; 7 of 8 patients reported reduced ulcer count, duration, and oral pain. The market's back, and these 3 income stocks are thriving. See them here→
Analysts Estimate MannKind ( MNKD ) to Report a Decline in Earnings: What to Look Out for
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Anika Therapeutics ( ANIK ) Reports Q2 Loss, Tops Revenue Estimates
Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amgen ( AMGN ) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen ( AMGN ) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
Amgen ( AMGN ) Stock Falls Amid Market Uptick: What Investors Need to Know
Amgen (AMGN) reached $301.29 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. ( AMGN ) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - AstraZeneca ( NASDAQ:AZN )
Gefurulimab met primary and secondary endpoints in 260-patient Phase 3 gMG trial. Significant improvement seen in MG-ADL score by week 26, with no new safety concerns. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
This Is What Whales Are Betting On Amgen - Amgen ( NASDAQ:AMGN )
Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
